Lovastatin and simvastatin which are very potent cellular cholesterol biosynthesis Inhibitors, significantly affect the plasma lipoprotein concentration.
Introduction Methode
Lovastatin, a potent hypocholesterolaemic dr g has Experimental procedure a profound effect on plasma lipoprotein composition Whole plasma was incubated for l h at 37 °C with 0.1 -100 and concentration (l -4). Lovastatin inhibits cellular F™ 1 / 1 ofunlabelled lovastatin or s nvastatm or with 20 GBq/1 , , , . , ' . ' , . Γ t. r [butanoate-l- 14 C] Mevacor (lovastatin) with specific radioaccholesterol biosynthesis and mcreases the number of tivity of 1A MB q/ mg O r with [butanoate -1-' 4 C] Zocor (simlow density Upoprptehl (Lt>L) receptors on the sur-vastatin)ι with a similar concentration and with a similar specific face Of cells (5) . Plasma Concentration of LDL JS radioactivity. Lipoproteins were then separated by discontinv ' : -. uous density gradient idtracentnfugation (6) . Lipoprotems were determined by the LDL receptor activity which is the also treated d i rec tly in some experiments with 100 μιηοΐ/ΐ of result of the number of the receptors s well s the unlabeUed or labelled drugs for l h at 37 °C prior to Separation affinitv of the iinot>rotems for these receptors The b V ultracentrifugation. Lovastatin was solubilized in dimethyl 4inniiy 01 ine lipoprotems lor mese recepiorb. ine sulplloxide (DM SO), whereas simvastatin was solubilized in present st dy was undertaken to find out whether et h an ol. Control LDL preparations incubated under sim ar lovastatin s weM s simvastatin bind to plasma lipo-conditions with the appropriate solvents were always used for proWns and "bether such ta..rac<ion ff«,«, 4= ΪΪ^ΑΑΑ^ΚΤ'ΑϊίϊΑΚ physico-chemical properties of the ilipoprotems and d uring clinical dosage r nge from 0.1 to 1.0 μιηοΐ/ΐ (7, 8) . The their Interaction with cells.
plasma concentration of the drug is afiected by its absorption Bur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 10 ralc, its time in the intestine s well s by its rapid passagc through ihe liver, its high metabolic rate and its short plasma half lifc. The drugs were a generous gift from Merck Sharp and Dohmc Research Laboratories (Rahway N. J., U. S. A.).
Lipoproteins
Lipoprotein electrophoresis was carried out on cellulose acetate (9), on sodium dodecyl sulphate (SDS) polyacrylamide gels (10) and on non-denatured gradient gels (11 ]LDL (500 ng). After incubation for 4 h at room temperature, the wells were washed 3 times with phosphatebuffered saline, and binding (B) was determined. The maximum binding (B 0 ) was determined in wells where competing lipoprotein was not added. The results are expressed s the B/B 0 ratio and each point is the mean of two measurements (CV < 10%).
Lipoprotein fluidity
The steady-state fluorescence polarization of diphenylhexatriene incoφOΓated into lipoproteins was measured (16) . The analysis was carried out with a spectrofluorimeter equipped with polarizers. Lipoproteins (protein = 50 mg/1) were incubated with 100 μπιοΙ/1 diphenylhexatriene for 30 minutes at 37 °C. Fluorescence polarization measurements were carried out at various temperatures and the anisotropy was determined. The anisotropy parameter is inversely related to the fluidity and is given s [(r 0 /r -1)] where r is the fluorescent anisotropy obtained from the polarization analysis and r 0 is the upper theoretical limit of the anisotropy.
Cells
Monolayer cultures of J-774A.1 murine macrophage-like cells were grown and maintained in Dulbecco Modified Eagles Medium (DMEM) supplemented with a 0.1 volume fraction of fetal bovine serum, penicillin (100 · 10 3 U/l), streptomycin (100 mg/1) and glutamine (2 mmol/1). The cells were fed twice every week. Human skin fibroblasts were cultured form punch biopsies of the skin of the anterior thigh from normal volunteers. Subcultures were used between passages 4-12. The cells were plated at 5 χ ΙΟ 5 cells/35-mm dishes in DMEM supplemented with a 0.1 volume fraction of fetal calf serum, 100 · 10 3 U/l penicillin, 100 mg/1 streptomycin, and 2 mmol/1 glutamine. After five days in culture, the medium was changed to DMEM supplemented with a 0.1 volume fraction of human lipoproteindeficient serum (d > 1.25 kg/l, prepared by ultracentrifugation) for 48 h to upregulate cellular LDL receptors. (17) . Cell-free LDL degradation was minimal and was subtracted from total LDL degradation. The cell layer was washed three times with phosphate-buffered saline and extracted by a l h incubation at room temperature with 0.5 ml of 0.1 mol/1 NaOH for measurement of protein.
Statistics
Results are given s mean ± by the Wilcoxon rank test.
S. D. Significance was analysed

Results
The partition of lovastatin and simvastatin among the various plasma lipoproteins was studied by incubating whole plasma from iiormolipidaemic subjects for l h with 10 μιηοΐ/ΐ of 14 C-labelled lovastatin or simvastatin, followed by lipoprotein Separation (using discontinuous density gradient ltracentrifugation). Table l demonstrates that the largest fraction of radioactivity (38%) was associated with high density lipoproteins (HDL). The drugs were also assoqiated with very low density lipoprotein (VLJDL) and l w density lipoprotein (LDL), while 20-30% of the radioactivity was recovered in the lipoprotein-deficient plasma fraction. When expressed per mg pf protein, the drug binding capacity was similar for all lipoproteins (tab. 1).
The binding capacity of simvastatin for HDL, LDL and VLDL was, however, 3, 4 and 6 times greater, respectively^ than that of lovastatin (tab. 1). The addition of 10 fold excess unlabelled lovastatin or sim- Whole plasma was incubated with 20 MBq/1 of 14 C-labelled lovastatin or simvastatin (100 μιηοΐ/ΐ) for l h at 37 °C, followed by lipoprotein Separation using discontinuous density gradient ultracentrifugation. Radioactivity was determined in each fraction and expressed s percent of total radioactivity (%) or s ng of drug associated with l mg of lipoprotein protein. The study was carried out under similar conditions to those described in table 1. vastatin to the plasma for the period of incubation with the labelled dr g resulted in 45% and 31% reduction in LDL-associated drug respectively, suggesting specific drug binding to the lipoproteins. To study the effect of lovastatin at concentrations below those present in plasma during clinical dosage, plasma was incubated for l hour with labelled lovastatin at concentrations of 0.1, 1,0 and 10 μτηοΐ/ΐ, and the distribution of the radioactivity was determined (tab. 2). The results revealed a similar pattern to that shown with 100 μπιοΐ/ΐ of lovastatin (tab. 1). The levels of LDL cholesterol, phospholipids and protein were unchanged after lipoprotein incubation with the drugs (data not shown).
In lipoprotein electrophoresis ori cellulose acetate, VLDL, LDL and HDL (protein = l g/l) that had been incubated with 100 μιηοΐ/ΐ lovastatin showed a substantially reduced electrpphoretic mobility ( fig. 1 ). Electrophoretic mobility of 100, as analysed by non-denatured gradient gels and by SDS polyacrylamide gel electrophoresis (data not shown). Both lovastatin-and simvastatin-associated LDL, like native LDL, showed minimal oxidation (0.3 -0.7 nmol malondialdehyde equivalents per mg protein). Simvastatin-and lovastatin-treated LDL displayed reduced electrophoretic mobility ( fig. 2 ) and this could not be attributed to the drug solvents (DMSO or ethanol, fig. 2 ). Pravastatin however, which is an open acid molecule, did not affect lipoprotein electrophoretic mobility (data not shown).
Lovastatin was found to affect lipoprotein fluidity, mainly that of LDL. The fluidity of lovastatin-treated LDL was increased by 28% in comparison with the fluidity of control LDL ( fig. 3 ). The effect of the drugs on LDL immunoreactivity was tested using monoclonal antibody Bl B6, which is directed towards the LDL receptor binding domains on apolipoprotein B-100. Figure 4 demonstrates the reduced immunoreactivity of lovastatin-and simvastatin-associated LDLs in comparison with control LDL treated with either DMSO or ethanol.
ED -25 vahies (the concentration of unlabelled lipoprotein required to reduce the immuiioreactivity to 25% of control) for lovastatin-and simvastatintreated LDL were 27 and 25 mg/1 compared with 12 and 9 mg/1 for the appropriate controls, respectively ( fig. 4) . Analysis of drug binding to macrophages revealed that both lovastatin and simvastatin bind to macrophages (tab. 3). C-labelled simvastatin. Drug-associated LDLs were prepared by inc bation of plasma with the labelled drugs followed by Separation. Cells were washed (x3) with phosphate-buffered saline and cell-associated radioactivity was determined. Drugs were used at two c ncentrations: A -100 μτηοΐ/ΐ, B -l umol/1. Results are mean ± S. D. of 3 experiments.
At lower, more physiological c ncentrations, however, drug binding to the cells increased; simvastatin binding to the cells was about twice that of lovastatin. The binding efficiency of each drug was substantially higher when it was introduced to the cells in association with LDL, rather than s the free compound (tab. 3 ).
The effect of drug treatment of LDL on its cellular binding, uptake and degradation were studied in J-774 A. l macrophage-lile cell Hne and in human skin I-labeiled lipoproteins (that were previously treated with drugs or with solvente) for 5 h at 37 °C. Cellular cholesterol esterification rate and macrophage degradation of the lipoproteins were analysed s described under Methods. The liproproteins were pretreated with the drugs (100 μιηοΐ/ΐ or l μηιοΐ/ΐ) for l hour at 37 °C followed by LDL Separation (by ultracentrifugation). Control LDLs were similarly prepared but they were treated with the appropriate solvents instead of drugs. Results are mean ± S. D. of 3 experiments *p < 0.01 (vs. the appropriate control). DMSO -Dimethylsulphoxide.
fibroblasts. Lovastatin-treated [ 1?5 I]LDL (protein = 25 mg/1) binds at 4 °C to macrophages 28% less than control LDL (350 + 37 Vs. 448 + 49 ng/mg cell protein respectively, n = 3). Similarly, the binding of lovastatin-treated LDL to human skin fibroblasts was reduced by 27% (from 839 ± 39 to 611 ± 44 ng/mg cell protein, n == 3). The cellular uptake of lipoproteins (protein = 25 mg/1)* s assessed by the macrophage cholesterol esterification rate, however, showed a 83% and 67% increased uptake of lovastatin (100 μmQl/l)-treated LDL and simvastatin-treated LDL respectively, in comparison with the control LDLs (tab. 4). Similarly, the macrophage degradation of these drug-associated LDLs increased by 89% and 87%, respectively (tab. 4). Similar effects were observed when a drug concentration of only l μιηοΐ/ΐ was used (tab. 4). In human skin fibriblasts, the ceU lular degradation of control LDL and lovastatintreated LDL (f 00 μιήοΐ/ΐ and l μπιοΐ/l of lovastatin) were 1991 ± 101, 3893 ± 233 and 2713 ± 188 ng/ mg cell protein respectively (n = 3). Figure 5 shows lipoprotein dose response curves for the macrophage degradation of lovastatin-associated LDL and of native LDL. At all lipoprotein concentrations studied, the cellular degradation of lovastatin-associated-LDL was substantially higher than that of the untreated lipoproteins ( fig. 5) . Analysis of the data by the Lineweaver-Burk plot revealed that the "apparent V max " for lovastatin-associated LDL was 1.7 times higher than that for native LDL, with no significant effect on "apparent K m " (fig. 5, insert) . Macrophage degradation of lovastatin-associated [ 125 ]LDL (LDL-LOV, protein =10 mg/1) was substantially reduced by 500 mg/1 of unlabelled lovastatin-associated LDL (from 345 ± 35 to 75 ±17 ng/mg cell protein per 5h). When native unlabelled LDL or acetyl LDL were used at similar concentrations, the cellular degradation of lovastatin-associated [ 125 I]LDL was 89 ± 24 and 337 ± 29 ng/mg cell protein, respectively, suggesting that lovastatin-associated LDL binds to the macrophage LDL receptor and not to the scavenger receptor.
Discussion
The present study demonstrates the binding of lovastatin and siinvastatin to plasma lipoproteins over a wide r nge of concentrations including those found in plasma during clinical dosage. Such drug binding was shown to affect lipoprotein physico-chemical characteristics, including reduced lipoprotein electro-phoretic mobility, increased fluidity and reduced immunoreactivity witli the monoclonal antibody B1B6, which is directed against the LDL receptor binding domains on apolipoprotein B-100. Uptake of drugassociated LDL by macrophages and fibroblasts was higher than that of native LDL. Even though the drugs may reduce the affinity of LDL for the LDL receptor, the net effect of the drug was to increase cellular uptake of the lipoprotein. This effect resulted from the increased number of LDL receptors on the cell surface which more than compensated for the reduced binding affinity of drug-treated LDL for the LDL receptor.
It is of interest that simvastatin showed increased binding to lipoproteins and macrophages in comparison with lovastatin. This may be related to the additional methyl group on the simvastatin molecule (l 8). Lovastatin and simvastatin, which are administered äs the lactone forms, are present in the systemic circulation. both äs open chain acids (62%) and äs closed-ring lactones (38%), both of which are potentially active (7) . In the present study we used the lactone forms of the drugs. Although the active form of lovastatin is the acid, there are also many other active metabolites (19) . The presence of non-metabolized lovastatin in the circulation (äs the lactone) can affect cellular metabolism of LDL via mechanism other than Inhibition of cellular cholesterol synthesis. Cellular uptake of the drugs may also result in the hydrolysis of the lactone to the acid form, thus causing cellular cholesterol biosynthesis Inhibition with subsequent increased synthesis of receptors for LDL. Recently it was shown that both lovastatin and simvastatin, when used in the lactone form, inhibited cholesterol biosynthesis in human monocyte-derived macrophages (20) .
The molecular size of the drug-treated lipoproteins was unchanged according to gradient gel electrophoresis analysis under non-denaturing conditions. Both drugs, however, reduced the electrophoretic mobility of LDL; this may be due to a changed conformation of the lipoprotein surface and the altered availability of charged surface phospholipids. It is well documented that the Charge of LDL affects its uptake by macrophages (21 -23) .
Increased uptake of LDL by macrophages has been demonstrated following lipoprotein oxidation (22, 23) . In our study, however, the drug did not affect the oxidation state of LDL. Furthermore, LDL apolipoprotein B-100 fragmentation, which is associated with lipoprotein oxidation (22) (23) (24) , did not take place in drug-associated LDL.
LDL fluidity was recently shown to be significantly reduced following incubation with platelet secretory products (25) . Lipoprotein fluidity depends on its cholesterol to phospholipid ratio and on its fatty acid composition (26) . Since the cholesterol and phospholipid contents were not changed in drug-associated LDL, it is possible that drug binding to the lipoprotein is associated with its interaction with phospholipid fatty acids. The increased lipoprotein fluidity observed in lovastatin-associated LDL may contribute to the enhanced cellular uptake of drug-associated LDL. Increased LDL fluidity following lovastatin therapy in hypercholesterolaemic patients was recently demonstrated in our laboratory (Aviram, M. et al., unpüblsihed observation).
Both drugs reduced the immunoreactivity of LDL towards monoclonal antibody B1B6, which recognizes epitopes at the LDL receptor binding domains of apolipoprotein B-100. This reduced immunoreactivity of the modified LDL may be related to the changes in lipoprotein Charge, äs suggested from the reduction in its electrophoretic mobility. Whereas the free drugs bind poorly to macrophages and fibn> blasts, they bind substantially to these cells when associated with LDL. This pheüomenon is the result of the high binding affinity of the lipoprotein for cells (27) . It is possible that in vivo LDL is responsible for delivering the drugs into the cells. The hypocholesterolaemic effect of the drugs is related to their ability to inhibit the rate-limiting enzyme of cholesterol biosynthesis, hydroxymethylglutaryl-coenzyme A reductase (HMG-CoA reductase) (l, 2). This effect in turn results in increased synthesis of of LDL receptors (28), and thus more LDL can be taken up by the cells and plasma cholesterol is reduced. The present study showed that the "apparent V raax " for lovastatin-associated LDL was higher than that for control LDL, suggesting that the drug increased the number of LDL receptors on the cell surface (probably following its intracellularconversion to the active acid form). From the reduced immunoreactivity of drug-associated LDL with the monoclonal antibody B1B6 and from its reduced cellular binding affinity, it can be expected that its uptake by the macrophage LDL receptor will be also reduced. In our study however, drug-associated LDLs were taken up and degraded by macrophages and by fibroblasts at increased rate in comparison with native LDL. Drug binding to LDL may cause conformational changes in apolipoprotein B-100 (äs suggested from the reduced immunoreactivity of drug-associated LDL with the monoclonal antibody B1B6) and this in turn could reduce the affinity of the lipoprotein for the cellular LDL receptor. On the other band, the ability of LDL to effectively deliver drug into the cells via the LDL receptor pathway, contributes to a specific Inhibition of HMGCoA reductase with a subsequent reduction in cellular cholesterol biosynthesis and an induction of LDL receptor synthesis. This latter effect of lovastatin, which results in an increased number of LDL receptors on the cell surface, is the major effect of the drug on the cellular uptake of LDL, since the net effect of lovastatin-associated LDL was to increase the cellular uptake and degradation of the lipoprotein. Thus, the reduced affinity of lovastatin-associated LDL for the LDL receptor might contribute far less to the cellular uptake of the lipoprotein than the increased number of LDL receptors. In certain pathological conditions, the magnitude of the opposing effects of lovastatin on LDL uptake by macrophages would determine the amount of cellular cholesterol accumulation.
